Becatecarin
- Generic Name
- Becatecarin
- Drug Type
- Small Molecule
- Chemical Formula
- C33H34Cl2N4O7
- CAS Number
- 119673-08-4
- Unique Ingredient Identifier
- A60X6MBU6G
- Background
Becatecarin is a derivative of rebeccamycin.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), liver cancer, gastric cancer, and leukemia (unspecified).
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
- Conditions
- LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00004189
- Locations
- ๐บ๐ธ
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
๐บ๐ธCancer Therapy and Research Center, San Antonio, Texas, United States
๐บ๐ธSt. Luke's Lutheran Hospital, San Antonio, Texas, United States
Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003737
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
- Conditions
- Extrahepatic Bile Duct CancerGallbladder CancerLiver Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT00005997
- Locations
- ๐บ๐ธ
Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธIreland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
๐บ๐ธHillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.